Hemoteq is a leading specialist in the market for biocompatible and drug eluting surfaces.
The company develops ultra-thin functional coatings and surface modification solutions for medical devices, supports its customers with comprehensive services around obtaining regulatory approval, and provides high-level clean room capacities for volume production. The application focus is on cardiology, ophthalmology, orthopedics, and dentistry. Hemoteq has a large customer base that includes leading European, North American, and Asian medical device manufacturers.
PINOVA acquired the stake of an existing shareholder in April 2010 and supported further international growth of the company.
In August 2015, PINOVA sold its shares to Freudenberg Group.